BMB-101 is under clinical development by Bright Minds Biosciences and currently in Phase I for Seizures. According to GlobalData, Phase I drugs for Seizures have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BMB-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BMA-101 is under development for the treatment of undisclosed seizure disorder, Dravet Syndrome opioid use disorder, binge eating disorder and Alzheimer's disease. It acts by targeting 5-hydroxytryptamine receptor 2C (5 HT2C). It is administered through oral route.
Bright Minds Biosciences overview
Bright Minds Biosciences (Bright Minds) is a biotechnology company that discovers and develops treatments for neuropsychiatry disorders, epilepsy, and pain. The company is investigating serotonin agonists targeting 5-HT2C, 5-HT2A/C, and 5-HT2A receptors to treat undisclosed seizure, opioid use, binge eating disorder; Alzheimer’s disease; depression; post-traumatic stress disorder (PTSD); and undisclosed chronic pain disorder. It utilizes intelligent drug design and advanced molecular modelling technology to develop its products. The company works in collaboration with the National Institutes of Health (NIH), University Of Texas Medical Branch, Medical College of Wisconsin and Katholieke Universiteit Leuven. Bright Minds is headquartered in Vancouver, British Columbia, Canada.
For a complete picture of BMB-101’s drug-specific PTSR and LoA scores, buy the report here.